Beijing Beilu Pharmaceutical Co., Ltd. (300016) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beijing Beilu Pharmaceutical Co., Ltd.

Why is Beijing Beilu Pharmaceutical Co., Ltd. ?

With a growth in Operating Profit of 24.59%, the company declared Outstanding results in Mar 26

The company has declared positive results for the last 5 consecutive quarters
OPERATING CASH FLOW(Y) Highest at CNY 255.83 MM
NET SALES(HY) At CNY 652.96 MM has Grown at 21.7%
ROCE(HY) Highest at 6.18%

With ROE of 3.36%, it has a fair valuation with a 1.33 Price to Book Value

Over the past year, while the stock has generated a return of -12.56%, its profits have risen by 775.5% ; the PEG ratio of the company is 0.1
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Beijing Beilu Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beijing Beilu Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Beijing Beilu Pharmaceutical Co., Ltd.

-12.56%

1.51

46.18%

China Shanghai Composite

21.43%

1.55

13.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.18%

EBIT Growth (5y)

-9.88%

EBIT to Interest (avg)

2.51

Debt to EBITDA (avg)

0.83

Net Debt to Equity (avg)

0.16

Sales to Capital Employed (avg)

0.39

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

3.85%

ROE (avg)

2.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.33

EV to EBIT

29.59

EV to EBITDA

16.59

EV to Capital Employed

1.35

EV to Sales

2.34

PEG Ratio

0.05

Dividend Yield

ROCE (Latest)

4.57%

ROE (Latest)

3.36%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

30What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 255.83 MM

NET SALES(HY)

At CNY 652.96 MM has Grown at 21.7%

ROCE(HY)

Highest at 6.18%

RAW MATERIAL COST(Y)

Fallen by -9.34% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -6.75 %

PRE-TAX PROFIT(Q)

Highest at CNY 51.93 MM

NET PROFIT(Q)

Highest at CNY 42.57 MM

-2What is not working for the Company

INTEREST(Q)

At CNY 3.39 MM has Grown at 31.41%

Here's what is working for Beijing Beilu Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 51.93 MM has Grown at 260.54%

over average net sales of the previous four periods of CNY 14.4 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 42.57 MM has Grown at 234.27%

over average net sales of the previous four periods of CNY 12.74 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Cash Flow

Highest at CNY 255.83 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

At CNY 652.96 MM has Grown at 21.7%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

Highest at CNY 51.93 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 42.57 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -6.75 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -9.34% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Beijing Beilu Pharmaceutical Co., Ltd.

Interest

At CNY 3.39 MM has Grown at 31.41%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)